Selected Grants
A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
Clinical TrialPrincipal Investigator · Awarded by Ocular Therapeutix Inc · 2024 - 2029A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants with Neovascular Age-related Macular Degeneration and Fellow Eye Treatment Substudy
Clinical TrialPrincipal Investigator · Awarded by Regenxbio, Inc. · 2024 - 2029Screening for Advanced Dry Age-Related Macular Degeneration in assisted living centers
Clinical TrialPrincipal Investigator · Awarded by Apellis Pharmaceuticals, Inc · 2023 - 2028GR43828 - A Phase I, Multicenter, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7446603 Alone and Co-Administered with Aflibercept in Patients with Diabetic Macular Edema
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2023 - 2028Evaluation of the Safety and Efficacy of Sustained Release Dexamethasone Intracanalicular Insert (Dextenza) in pediatric patients following retinal surgery or laser treatment under anesthesia (TENDER)
Clinical TrialPrincipal Investigator · Awarded by Ocular Therapeutix Inc · 2022 - 2027A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
Clinical TrialPrincipal Investigator · Awarded by Ocular Therapeutix Inc · 2024 - 2029A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants with Neovascular Age-related Macular Degeneration and Fellow Eye Treatment Substudy
Clinical TrialPrincipal Investigator · Awarded by Regenxbio, Inc. · 2024 - 2029Screening for Advanced Dry Age-Related Macular Degeneration in assisted living centers
Clinical TrialPrincipal Investigator · Awarded by Apellis Pharmaceuticals, Inc · 2023 - 2028GR43828 - A Phase I, Multicenter, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7446603 Alone and Co-Administered with Aflibercept in Patients with Diabetic Macular Edema
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2023 - 2028Evaluation of the Safety and Efficacy of Sustained Release Dexamethasone Intracanalicular Insert (Dextenza) in pediatric patients following retinal surgery or laser treatment under anesthesia (TENDER)
Clinical TrialPrincipal Investigator · Awarded by Ocular Therapeutix Inc · 2022 - 2027A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of Suprachoroidal Administration of RGX-314 for Diabetic Retinopathy Without Center Involved-Diabetic Macular Edema
Clinical TrialPrincipal Investigator · Awarded by Regenxbio, Inc. · 2022 - 2027A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD
Clinical TrialPrincipal Investigator · Awarded by Regenxbio, Inc. · 2022 - 2027HORIZON: A Phase II, Open-Label, Outcomes-Assessor Masked, Multicentre, Randomised, Controlled Study To Evaluate The Safety And Efficacy Of TwoDoses Of Gt005 Administered As A Single Subretinal Injection In Subjects With Geographic Atrophy Secondary
Clinical TrialPrincipal Investigator · Awarded by Medpace, Inc · 2021 - 2026A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE)
Clinical TrialPrincipal Investigator · Awarded by Regenxbio, Inc. · 2021 - 2026A PHASE III, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINOPATHY (PAVILION)
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2020 - 2025A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Macular Edema
Clinical TrialPrincipal Investigator · Awarded by F. Hoffmann-La Roche Ltd · 2020 - 2025Evaluation of the Heidelberg Engineering SPECTRALIS with Flex Module for In-vivo Imaging in the Supine Position
Clinical TrialPrincipal Investigator · Awarded by Heidelberg Engineering · 2020 - 2025Applying artificial intelligence to pediatric retinal screening based on ultra-widefield fundus imaging
ResearchPrincipal Investigator · Awarded by VitreoRetinal Surgery Foundation · 2023 - 2024Implementation of ultra-wide field fundus photography for pediatric retinal screening within a primary care setting
ResearchPrincipal Investigator · Awarded by VitreoRetinal Surgery Foundation · 2023 - 2024Optimizing vitrectomy technique and parameters for subretinal gene therapy: An intraoperative OCT based volumetric study
ResearchPrincipal Investigator · Awarded by VitreoRetinal Surgery Foundation · 2023 - 2024Repeatability, Reproducibility, and Characterization of Choroidal Vascularity Index (CVI) in Handheld versus Tabletop OCT images in adults and premature infants
FellowshipPrincipal Investigator · Awarded by VitreoRetinal Surgery Foundation · 2022 - 2024Intraoperative OCT Guidance of Intraocular Surgery
ResearchCo Investigator · Awarded by National Institutes of Health · 2018 - 2024A Phase 2, Outcomes Assessor-Masked, Multicentre, Randomised Study to Evaluate the Safety and Efficacy of Two Doses of Gt005 Administered as A Single Subretinal Injection in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degenerati
Clinical TrialPrincipal Investigator · Awarded by Gyroscope Therapeutics Limited · 2023 - 2024Volumetric Measurement of Subretinal Blebs Created with Orbit Subretinal Delivery Device and Using Microscope-Integrated Optical Coherence Tomography
Clinical TrialPrincipal Investigator · Awarded by Gyroscope Therapeutics Limited · 2018 - 2023Serum Anti-AAV8 Neutralizing Antibody Assessment Study of Patients with Neovascular Age-related Macular Degeneration or Diabetic Retinopathy
Clinical TrialPrincipal Investigator · Awarded by Regenxbio, Inc. · 2020 - 2023Screening for pediatric retinal diseases using artificial intelligence and wide-field fundus imaging
ResearchPrincipal Investigator · Awarded by VitreoRetinal Surgery Foundation · 2021 - 2023A retrospective study of subjects previously enrolled in ADX-2191-PVR-001, assessing the development of epiretinal membranes post silicone oil removal
ResearchPrincipal Investigator · Awarded by Aldeyra Therapeutics · 2022 - 2023A multicenter, randomized, controlled, prospective, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy
Clinical TrialPrincipal Investigator · Awarded by Aldeyra Therapeutics · 2020 - 2023Evaluation of chronic effects of electronic cigarette aerosol inhalation on macular perfusion using optical coherence tomography angiograph
FellowshipPrincipal Investigator · Awarded by VitreoRetinal Surgery Foundation · 2019 - 2022Psychophysics-Guided Signal Processing for Retinal Prosthetics
ResearchCo Investigator · Awarded by National Institutes of Health · 2018 - 2021The Impact of Choroidal Thickness in Retinopathy of Prematurity: A Longitudinal Stud
FellowshipPrincipal Investigator · Awarded by VitreoRetinal Surgery Foundation · 2019 - 2021Second Sight Argus II (PM-02-01)
Clinical TrialPrincipal Investigator · Awarded by Second Sight Medical Products, Inc · 2013 - 2021Comparison of subretinal bleb volumes created by ab-externo and ab-interno approaches using microscope-integrated optical coherence tomography.
FellowshipPrincipal Investigator · Awarded by The Robert Machemer Foundation · 2019 - 2020Using Optical Coherence Tomography Angiography to Analyze Development of Pediatric Retinal Vasculature
FellowshipPrincipal Investigator · Awarded by VitreoRetinal Surgery Foundation · 2019 - 2020Subretinal drug delivery via a novel ab-externo approach using microscope integrated optical coherence tomography
ResearchPrincipal Investigator · Awarded by VitreoRetinal Surgery Foundation · 2018 - 2020GX29633 PROXIMA
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2015 - 2019Photoceptor development in premature vs term infants
ResearchPrincipal Investigator · Awarded by Knights Templar Eye Foundation, Inc. · 2013 - 2016External Relationships
- AbbVie, Inc.
- AbbVie, Inc.
- Alcon, Inc
- Alcon, Inc
- Alimera Sciences
- AbbVie, Inc.
- AbbVie, Inc.
- Alcon, Inc
- Alcon, Inc
- Alimera Sciences
- Alimera Sciences
- Apellis Pharmaceuticals
- Apellis Pharmaceuticals
- Astellas Pharma Inc.
- Astellas Pharma Inc.
- Beaver Visitec International Inc.
- Beaver Visitec International Inc.
- Best Doctors-Teledoc Health
- Best Doctors-Teledoc Health
- Broadcastmed Holdco LLC
- Broadcastmed Holdco LLC
- Bryn Mawr Communications, LLC
- Bryn Mawr Communications, LLC
- Clearside Biomedical
- Clearside Biomedical
- Dutch Ophthalmic Research Center
- Dutch Ophthalmic Research Center
- EyePoint
- EyePoint
- Genentech
- Genentech
- Guidepoint Global
- Guidepoint Global
- Healio Strategic Solutions LLC
- Healio Strategic Solutions LLC
- IVista Medical Education
- IVista Medical Education
- Iveric Bio
- Lexitas
- Lexitas
- MedForce Inc
- Nanoscope
- Ocugen, Malvern, PA
- Ocugen, Malvern, PA
- Ocular Therapeutix Inc.
- Ocular Therapeutix Inc.
- Oculus Surgical
- Oculus Surgical
- Outlook therapuetic
- Outlook therapuetic
- PharMethod, Inc.
- PharMethod, Inc.
- Phoenix Group Holdings, DBA Enova
- Phoenix Group Holdings, DBA Enova
- Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals
- Regenexbio
- Regenexbio
- Vindico
- Vindico
- i2Vision
- i2Vision
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.